Drugs in Dev. Pulmonary/Respiratory Diseases
Phase II/ Phase III
Germany 
Lead Product(s) : Ifx-1
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
InflaRx Gets CHMP Opinion for GOHIBIC® for SARS-CoV-2 ARDS Treatment
Details : Gohibic (vilobelimab) is a first-in-class monoclonal anti-human complement factor C5a antibody being evaluated for treating acute respiratory distress syndrome.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
November 15, 2024
Lead Product(s) : Ifx-1
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Alteplase
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Alteplase is a Enzyme drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Respiratory Distress Syndrome.
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
November 23, 2020
Lead Product(s) : Alteplase
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fluticasone Propionate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Fluticasone Propionate is a Steroid drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome.
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
February 29, 2016
Lead Product(s) : Fluticasone Propionate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fluticasone Propionate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Flutiform® Compared With Seretide® in the Treatment of COPD
Details : Fluticasone Propionate is a Steroid drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Pulmonary Disease, Chronic Obstructive.
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
July 21, 2014
Lead Product(s) : Fluticasone Propionate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cyclosporine
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
L-CsA in the Prevention of Bronchiolitis Obliterans Syndrome (BOS) in Lung Transplant (LT) Patients
Details : Cyclosporine is a Peptide drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Bronchiolitis Obliterans.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
April 13, 2011
Lead Product(s) : Cyclosporine
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
